Phenotypes associated with this allele

• Allele Symbol: Hprt1^{tm6(CAG-fat-1)Geno}
• Allele Name: targeted mutation 1, Genoway
• Allele ID: MGI:5629842
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Hprt1^tm6(CAG-fat-1)Geno/Y Gt(ROSA)26Sor^tm1(cre/ERT2)Tyj/Gt(ROSA)26Sor^+	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6	MGI:5629844
cn2	Gt(ROSA)26Sor^tm1(cre/ERT2)Tyj/Gt(ROSA)26Sor^+ Hprt1^tm6(CAG-fat-1)Geno/Hprt1^tm6(CAG-fat-1)Geno	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6	MGI:5629845

Genotype
MGI:5629844

cn1

• Allelic Composition: Hprt1^{tm6(CAG-fat-1)Geno}/Y; Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

homeostasis/metabolism

abnormal fatty acids level ( J:213660 )

♂ • tamoxifen-treated mice exhibit enrichment in phospholipid total n-3 polyunsaturated fatty acid (predominantly docosahexaenoic acid) with lesser contributions to total relative n-3 polyunsaturated fatty acid enrichment from 22:5n-3 in the liver, kidney and muscle compared with control mice

♂ • tamoxifen-treated mice exhibit a reduction in n-6 polyunsaturated fatty acid species, 22:5n-6 and 22:4n-6 in the liver, kidney and a small overall decrease in total n-6 polyunsaturated fatty acid content in the kidney and liver compared with control mice

♂ • tamoxifen treated mice exhibit a small difference in n-6/n-3 polyunsaturated fatty acid ratio compared with control mice

♂ • however, mice exhibit normal total saturated fatty acid, monounsaturated fatty acid and polyunsaturated fatty acid

Genotype
MGI:5629845

cn2

• Allelic Composition: Gt(ROSA)26Sor^{tm1(cre/ERT2)Tyj}/Gt(ROSA)26Sor⁺; Hprt1^{tm6(CAG-fat-1)Geno}/Hprt1^{tm6(CAG-fat-1)Geno}
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6

homeostasis/metabolism

abnormal fatty acids level ( J:213660 )

♀ • tamoxifen-treated mice exhibit enrichment in phospholipid total n-3 polyunsaturated fatty acid (predominantly docosahexaenoic acid) with lesser contributions to total relative n-3 polyunsaturated fatty acid enrichment from 22:5n-3 in the liver, kidney and muscle compared with control mice

♀ • tamoxifen-treated mice exhibit a reduction in n-6 polyunsaturated fatty acid species, 22:5n-6 and 22:4n-6 in the liver, kidney and a small overall decrease in total n-6 polyunsaturated fatty acid content in the kidney and liver compared with control mice

♀ • tamoxifen treated mice exhibit a small difference in n-6/n-3 polyunsaturated fatty acid ratio compared with control mice

♀ • however, mice exhibit normal total saturated fatty acid, monounsaturated fatty acid and polyunsaturated fatty acid